The materials list was not terribly grand: a beer bottle, some crystal cat litter, a little diatomaceous earth, ordinary sand. The job was one of molecular biology's most routine chores, purifying plasmid DNA. Most laboratories buy a kit. Joe Rokicki wanted to know what the kit was actually doing, so he crushed the sort of objects that turn up in a recycling bin or a pet aisle and tested them as substitutes for the silica inside the commercial column.
The beer-bottle glass worked, though it seemed to damage some of the DNA. Crushed crystal cat litter worked about as well as the commercial product. Sand was useless. Rokicki published the results in 2014 under the cheerfully literal title Beer Bottle Minipreps. It is a small experiment, ingenious without being precious, and a handy miniature of his career. Take apart the black box. Understand the mechanism. Borrow whatever discipline or material the problem demands. Then build.
The course nobody quite knew how to classify
Rokicki arrived at Princeton in 2004 as an electrical engineering student. That year, the university was piloting an integrated science sequence associated with molecular biologist David Botstein. Instead of arranging physics, chemistry, biology and computing in their customary separate rooms, the course treated them as parts of one conversation. Advisers were cautious. An unconventional sequence could make conventional prerequisites inconvenient. Rokicki enrolled anyway.
His explanation at the time was wonderfully free of strategy: “It's everything I wanted to do in college all in one class.” The sentence sounds less like a comment on a course than an early draft of his résumé. He would keep looking for places where the whole complicated thing could fit in one room.
In 2007, that appetite carried him to the University of Edinburgh's team in the International Genetically Engineered Machine competition, better known as iGEM. One project tried to make self-flavouring yogurt. It was playful and technically serious, an attempt to treat living systems as an engineering medium. Rokicki later described the experience as the point when he fell for biology.
“It's everything I wanted to do in college all in one class.”Joe Rokicki, on Princeton's integrated science sequence
After Princeton, he went to the University of Colorado Boulder for doctoral work in molecular, cellular and developmental biology. He studied bacterial evolution and enzymology, but his engineering and programming did not disappear politely. He became the lab's in-house coder, the person who could make the computational part of a project exist when it did not already come in a box.
A night-light that would not hurry
In 2012, Rokicki and fellow graduate student Tim Read helped establish CU Boulder's first iGEM team. The students read stacks of papers, argued through possibilities and settled on a bacterial night-light. They cloned six genes involved in bioluminescence from Aliivibrio fischeri. The cells, alas, declined to recognize the deadline. The team ran out of time before it produced meaningful light and did not advance beyond the regional semifinal.
This is how engineering biology introduces itself: as engineering, followed by a tactful correction from biology. Code can be rerun. A circuit can be measured. A cell brings history, context and moods of its own. Rokicki stayed interested in the negotiation.
His doctoral years also produced CodaChrome, an interactive heat map for comparing one bacterial proteome against all the others then available in GenBank. The task was partly biological and partly a problem of legibility. Thousands of genomes had created a great heap of relationships. CodaChrome made patterns visible: highly conserved proteins, fast-changing genes, traces of horizontal gene transfer. The instinct was familiar. When the science becomes too tangled to inspect, build an instrument for seeing it.
Circuits, enzymes and the pleasure of no silos
After his PhD, Rokicki joined Omniome, a next-generation DNA-sequencing company in San Diego. The attraction was not simply sequencing. It was the chance to engineer and solder circuits, program robotics and perform molecular biology in the same workplace. His name later appeared on patents covering nucleotide-detection methods, sequencing workflows and the stabilization of molecular complexes. They are inventions from a world where chemistry, optics, fluidics and software must agree before a base can be read.
Omniome's chief executive Kandaswamy Vijayan and Rokicki then helped found Plexium in 2017 with Andrew MacConnell. The company pursued targeted protein degradation, an approach that asks small molecules to recruit the cell's disposal machinery against chosen proteins. Rokicki helped take the company from a blank page to a working platform. Public patent records place him on inventions involving oligonucleotide-encoded chemical libraries, tools for testing enormous numbers of molecular interactions.
The experience also taught him a strategic lesson. A pure platform company can build remarkable machinery while remaining dependent on the priorities of pharmaceutical partners. It may own the engine but not the itinerary. Rokicki wanted the technical work connected to a product path the company could choose for itself.
“Always do what's best for the company's North Star.”Joe Rokicki's operating rule
Nature, converted from archive to search space
That desire helps explain Enveda. Founded by Viswa Colluru, the Boulder company set out to search the chemistry of the natural world for potential medicines. Plants and other organisms make a lavish range of molecules, but natural mixtures are notoriously unruly. A mass spectrometer can produce forests of signals without supplying every structure or biological function. The opportunity is enormous; so is the sorting problem.
Enveda's proposition was to combine metabolomics, machine learning, automation and biological testing. Rokicki joined as founding chief technology officer. Even at seed stage, the company had a preclinical pipeline and the intention to carry programs forward, not merely sell access to a platform. For a builder who had grown wary of elegant engines without a chosen destination, the difference mattered.
He ran what Enveda called the Research Accelerator, a group aimed squarely at zero-to-one work. Its job was to notice a missing capability, translate the problem among scientists and engineers, and get to proof of concept. August Allen's platform organization could then take successful experiments from one to one hundred. Their collaboration turned prototypes into internal products, including tools that helped Enveda scientists search molecular and assay information quickly.
Rokicki supplied a compact rationale for the whole enterprise: “Every metabolite in nature is made by a protein and for a protein.” Natural molecules are not a random chemical rummage sale. They emerged inside living systems, amid the proteins with which chemistry must interact. Evolution has already performed an unfathomably long experiment. Enveda is trying to make the notebook searchable.
The sentence also reveals how Rokicki reasons. It begins with a biological fact, turns it into a theory of where useful chemistry might be concentrated, and then implies an engineering program. If nature's metabolites are biased toward protein interaction, the challenge becomes one of access: collect the mixtures, measure their components, infer structures, test activity and connect promising signals to programs. None of those steps belongs to a single discipline. Together they resemble the integrated science course that first caught his attention two decades earlier, except now the exam is a working discovery system.
The useful career of a scientific translator
Enveda now lists August Allen as chief technology officer. Rokicki's title is Founding Fellow, a change that feels apt for someone whose best work begins before an organizational box has acquired a label. The Fellow can range. The founder remembers why the machinery exists.
There is a temptation to describe cross-disciplinary people as generalists, which can sound like a polite way of saying they have avoided choosing. Rokicki's record suggests something more exact. He repeatedly goes deep enough in several domains to translate among them: a biological question into a computational one, a laboratory bottleneck into an engineering project, a clever platform into a product decision. Translation here is not a meeting skill. It is an act of construction.
His public record has the useful messiness of that approach. Academic papers sit beside patents. A comparative-genomics visualization sits beside a kitchen-cupboard purification protocol. Company formation sits beside student mentoring. In 2022, he was among the Enveda authors on work using knowledge graphs and gene-expression signatures to reason about drug discovery. The methods are varied, but the question underneath is stable: how can scattered information be organized into a decision someone can act on?
The beer bottle is worth returning to. Rokicki did not discover that silica binds DNA. He took an established fact and made it tangible with discarded glass, salt and curiosity. Much of his career follows that rhythm. The raw knowledge exists. The natural molecules exist. The sequencing chemistry exists. The difficult and creative work is arranging them into something another person can use.
Science has excellent reasons for its specialties; companies have excellent reasons for their departments. The interesting trouble begins when the problem ignores both. That is usually where Joe Rokicki starts looking for tools.
Keep following the thread